Objective: Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. The aim of this phase 1 study was to evaluate the safety and tolerability of ramucirumab monotherapy in Japanese patients with advanced solid tumors. Methods: Patients with solid tumors who had not responded to standard therapy or for whom no standard therapy was available received escalating doses of ramucirumab, administered once every 2 (Q2W) or 3 (Q3W) weeks. The primary objective was to establish the safety and pharmacokinetic profiles of ramucirumab. Secondary and exploratory objectives included assessment of immunogenicity and antitumor activity. ClinicalTrials.gov: NCT01005355. Results: Fifteen patients were treated with ramucirumab at a dose of 6 mg/kg Q2W (N = 3), 8 mg/ kg Q2W (N = 6) or 10 mg/kg Q3W (N = 6). There were no dose-limiting toxicities and the maximum tolerated dose was not reached. The most common ramucirumab-related adverse events were headache, pyrexia, hypertension and increased aspartate aminotransferase. Following single-dose administration of ramucirumab, there appeared to be a dose-proportional increase in maximum observed drug concentration but not in area under the curve. Treatment-emergent anti-ramucirumab antibodies were not detected in any patient. Conclusions: Ramucirumab monotherapy was well tolerated and feasible at the doses and schedules used in this study population of Japanese patients with advanced solid tumors.
Introduction
Angiogenesis, the formation of new blood vessels from existing blood vessels, is essential for tumor growth, progression and metastasis (1) (2) (3) . Various signaling pathways are involved in the regulation of angiogenesis, including the vascular endothelial growth factor (VEGF) pathway, which consists of three tyrosine kinase VEGF receptors (VEGFR-1 to -3) and six VEGF ligands (VEGF-A to -E and placental growth factor [PlGF] ) (1) (2) (3) . Expression of VEGF and its receptors is upregulated in many solid tumor types, including breast, colorectal, gastrointestinal tract, liver, lung, kidney and thyroid cancers (1, 2) . In particular, VEGFR-2 appears to play an important role in tumor-related angiogenesis and is, therefore, a promising target for the development of anti-angiogenesis drugs (3, 4) . Several anti-angiogenesis drugs have been approved (3) , including bevacizumab (monoclonal antibody against VEGF-A), sunitinib and sorafenib (small molecule inhibitors of several tyrosine protein kinases, including VEGF-1 to -3), showing the feasibility of targeting components of the VEGF pathway in the treatment of cancer.
Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 with high affinity, thereby preventing VEGF ligands from binding to and activating VEGFR-2 (5) . Ramucirumab has been shown to inhibit VEGF-stimulated proliferation of endothelial cells and VEGF-induced migration of human leukemia cells (6) (7) (8) . Two phase 1 studies of ramucirumab monotherapy conducted in largely Caucasian study populations with advanced solid tumors showed ramucirumab to be well tolerated, with an acceptable safety profile and evidence of antitumor activity (5, 9) . In the multinational, randomized, double-blind, phase 3 REGARD study, ramucirumab monotherapy significantly improved overall survival compared with placebo in patients with advanced gastric or gastroesophageal junction cancer who had failed first-line chemotherapy (10) . These improvements in efficacy were accompanied by an acceptable safety profile (10) . The randomized, phase 3 RAINBOW, RAISE and REVEL studies showed that ramucirumab also significantly improved overall survival when given in combination with paclitaxel in patients with advanced gastric or gastroesophageal junction cancer (11) , with FOLFIRI (fluorouracil, folinic acid and irinotecan) in patients with metastatic colorectal carcinoma (CRC) (12) , and with docetaxel in patients with stage IV non-small cell lung cancer (NSCLC) (13) . Based on these studies, ramucirumab has been approved in several countries and regions including the USA, the European Union and Japan for second-line of gastric cancer, CRC and NSCLC (14) (15) (16) . However, additional information is needed on ramucirumab monotherapy for the treatment of Japanese patients with other types of solid tumors.
The aim of this phase 1 study was to evaluate the safety and tolerability of ramucirumab monotherapy over a dose range of 6-10 mg/kg, administered every 2 (Q2W) or 3 (Q3W) weeks, in Japanese patients with advanced solid tumors. The primary objective was to help establish the safety and pharmacokinetic (PK) profiles of ramucirumab in this study population. The secondary objective was assessment of immunogenicity and exploratory objectives included preliminary assessment of antitumor activity and assessment of the pharmacodynamic effects of ramucirumab.
Patients and methods

Study design
This was an open-label, single-center, single-arm, doseescalation, phase 1 study of ramucirumab in Japanese patients with advanced solid tumors conducted between September 2009 and January 2011. The study protocol was approved by the Institutional Review Board at the National Cancer Center. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and applicable local regulations. All patients provided written informed consent before study entry. The study was registered at www. clinicaltrials.gov (NCT01005355).
Study population
Patients with advanced primary or recurrent solid tumors (histologically or cytologically confirmed) who had not responded to standard therapy or for whom no standard therapy was available were eligible for inclusion in the study. The main inclusion criteria were: age ≥20 years; measurable or non-measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; and adequate hematologic, hepatic and renal function. The main exclusion criteria were: chemotherapy, radiotherapy or major surgery within 28 days before study entry or ongoing side effects of Grade ≥2 from agents administered more than 28 days earlier; subcutaneous venous access device placement within 7 days before study entry; previous treatment with agents that target VEGF or VEGFR; history of postoperative bleeding complications, wound complications from a surgical procedure or gastrointestinal perforation; and any Grade 3 or 4 gastrointestinal bleeding within 3 months before study entry.
Treatment
Patients were enrolled sequentially into three ramucirumab dose cohorts (Cohorts 1, 2 and 3: 6 mg/kg Q2W, 8 mg/kg Q2W and 10 mg/kg Q3W, respectively), each consisting of a minimum of three patients. The ramucirumab doses and treatment schedules were selected based on data from preclinical and clinical studies: 13 mg/kg identified as the maximum tolerated dose (MTD) for weekly administration, ≥6 mg/kg Q2W with minimum drug concentrations that exceeded those of DC101 (murine surrogate antibody) associated with antitumor activity in preclinical models and 6-13 mg/kg demonstrating preliminary clinical activities. Patients received 6, 8 or 10 mg/kg ramucirumab on Day 1, administered as an intravenous infusion over 1 hour, every 2 weeks (6 mg/kg, 8 mg/kg) or 3 weeks (10 mg/kg) for 6 weeks (one cycle). After one cycle of treatment and in the absence of any dose-limiting toxicity (DLT), patients who had an objective response or stable disease (SD) were permitted to receive ramucirumab at the same dose and schedule until disease progression, unacceptable toxicity or other withdrawal criteria were met. A patient was considered to have completed the study if they completed the initial 6-week treatment period (Cycle 1) or discontinued treatment because of a ramucirumab-related toxicity during Cycle 1.
Dose escalation method
Dose escalation of ramucirumab occurred sequentially over the doses of 6 mg/kg Q2W, 8 mg/kg Q2W and 10 mg/kg Q3W until the criteria for reaching the MTD were met or the highest planned dose cohort was completed. If two of six patients experienced a DLT in Cohort 1, the study was to be discontinued. If two of six patients experienced a DLT in Cohort 2, then Cohort 1 (6 mg/kg Q2W) would be considered the MTD. If no MTD was determined, Cohorts 2 and 3 were to be expanded to six patients to obtain sufficient serum ramucirumab concentration data for PK analysis. A DLT was defined as any of the following events assessed as definitely, probably or possibly related to ramucirumab: Grade 4 neutropenia lasting >7 days; Grade 4 anemia; Grade ≥3 thrombocytopenia; Grade ≥3 neutropenia associated with fever; Grade 3 or 4 non-hematologic toxicity; Grade 4 or uncontrollable hypertension.
Safety assessments
Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. Safety outcomes included AEs and DLTs.
PK analyses
For determination of serum concentrations of ramucirumab for PK analyses, serum samples were collected before the first infusion, immediately after the infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336 and 504 hours after the end of the first infusion. In addition, samples were collected: before the third infusion, immediately after the third infusion and 0.5, 1, 2, 4, 8, 24, 48, 96, 168, 264, 336 and 504 hours after the end of the third infusion; before and 1 hour after the end of the fifth infusion; before and 1 hour after the end of the infusion every 6 weeks thereafter; and at the end-of-therapy and end-of-study visits. PK outcomes included maximum observed drug concentration (C max ), area under the concentration versus time curve (AUC) and half-life (t 1/2 ). PK parameters were estimated by non-compartmental methods using WinNonlin ® 5.1 (Pharsight Corporation). Ramucirumab serum concentrations were measured using a bridging enzyme-linked immunosorbent assay (ELISA), as described previously (9) . It should be noted that this assay (which was also used in the two other phase 1 studies of ramucirumab monotherapy (5,9)) was subsequently modified (17-19) because of validation issues.
Immunogenicity
For detection of anti-ramucirumab antibodies, serum samples were collected before the first, fourth and seventh infusions and at the end-of-study visit. Ramucirumab immunogenicity was assessed using a validated ELISA (at BioAgilytix, Durham, NC, USA).
Antitumor activity
Tumor response was assessed by RECIST version 1.0 after every cycle (approximately every 6 weeks). Complete response (CR) was defined as the disappearance of all target lesions. Partial response (PR) was defined as at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum longest diameter. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as progressive disease (PD), taking as reference the smallest sum longest diameter since the treatment started. PD was defined as at least a 20% increase in the sum of the longest diameter of the target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started in comparison with the measurement of the nadir or the appearance of one or more new lesion(s). Antitumor activity was assessed by a best overall response, duration of response and duration of SD. The disease control rate (DCR) was defined as the proportion of patients with a CR, PR or SD. Duration of SD was measured from the start of the treatment until the criteria for PD were met.
Pharmacodynamic assays
Serum samples were collected for pharmacodynamics biomarker analysis at multiple time points, and were assayed from baseline, just prior to Dose 2 for the respective cohorts, at the end of the first 6-week cycle, and at the end of the study for those patients who continued on treatment and who had an available sample. Assays were performed for angiopoietin-1 and -2, basic fibroblast growth factor, c-KIT, C-reactive protein, E-selectin, hepatocyte growth factor, intercellular adhesion molecule-1 and -3, interleukin-4, -8 and -12, kinase insert domain receptor, P-selectin, PlGF, serum amyloid A, soluble Fms-like tyrosine kinase-1, stromal cell-derived factor-1A, thrombomodulin, vascular cell adhesion molecule-1, and VEGF-A, -C and -D using commercial ELISA kits, as described previously (5). Samples were assayed for Cohorts 2 and 3 only, as there were no samples available from Cohort 1 after the PK analyses.
Statistical analysis
The planned sample size was 15-18 patients. The actual sample size was determined by the incidence of DLTs and the resulting sizes of the cohorts. All enrolled patients who received at least 1 dose of study drug were evaluated for safety and efficacy. Descriptive statistics were used to summarize the study results; no formal statistics were conducted because of the non-randomized, single-arm nature of the study and the small sample size. Analyses were performed using SAS version 9.1.3 or above (SAS Institute, Cary, NC, USA).
Results
Patient disposition
A total of 17 patients were screened and enrolled in the study, of whom two patients did not receive ramucirumab: one patient experienced worsening of disease and was not assigned to a cohort and one patient was assigned to Cohort 2, but withdrew consent before receiving treatment. Three cohorts of three, six and six patients (Cohorts 1, 2 and 3, respectively) received ramucirumab treatment and were evaluated for safety and efficacy (N = 15). All 15 patients completed Cycle 1, after which 10 patients discontinued study treatment. The remaining five patients completed 2-8 cycles of treatment before discontinuing study treatment. Most patients (12 patients, 80.0%) discontinued from the study because of PD; there were no study discontinuations because of AEs or death.
Demographic and baseline clinical characteristics
Of the 15 patients in the 3 cohorts, 6 patients (40.0%) were male and 11 patients (73.3%) had an ECOG performance status of 0 ( 
Safety
Ramucirumab monotherapy was well tolerated in this study population. There were no DLTs and the MTD was not reached. There were no deaths and no patient discontinued the study because of an AE. There were five serious adverse events (SAEs): four patients were hospitalized for administrative reasons not associated with an AE or the study treatment and one patient experienced a treatmentrelated SAE (syncope). Five patients (33.3%) reported ≥1 treatmentemergent AE of Grade ≥3, of which one AE was treatment related (Grade 3 syncope reported by one patient in Cohort 3). Decreased sodium with deterioration of primary disease was the possible cause of syncope, whose relationship with infusion reaction was considered to be unlikely. All patients reported ≥1 treatment-related AE. The most common AEs of any grade considered related to ramucirumab were headache, pyrexia, hypertension and increased aspartate aminotransferase (Table 2) .
Pharmacokinetics
All 15 patients had sufficient serum ramucirumab concentration data for PK analysis following single-dose administration of ramucirumab (Cycle 1, Week 1) (Fig. 1A) ; five patients (one patient in Cohort 1 and two patients in each of Cohorts 2 and 3) had sufficient serum ramucirumab concentration data for PK analysis following repeated dosing (Cycle 2, Week 1) (Fig. 1B) . Following single-dose administration of ramucirumab, C max appeared to increase proportionally with increasing dose; there was no clear trend for a doseproportional increase in AUC. Ramucirumab had a relatively long half-life (129-329 hours) in the three cohorts. However, it should be noted that only 2-4 patients in each cohort had sufficient PK data for the estimation of the half-life. The small number of patients with sufficient serum concentration data following repeated dosing limits any conclusions about dose dependency on exposure following repeated dosing.
Immunogenicity
Treatment-emergent anti-ramucirumab antibodies were not detected in any patient during the study.
Efficacy
Across the three cohorts, eight patients (53.3%) had a best overall response of SD, six patients (40.0%) had PD and one patient (6.7%) could not be evaluated, resulting in a DCR of 53.3%. No patient had a CR or PR. The eight patients with SD (Cohort 1: one patient; Cohort 2: four patients; Cohort 3: three patients) had lung adenocarcinoma (two patients), adenocarcinoma-primary site unknown (one patient), uterine leiomyosarcoma (one patient), retroperitoneal leiomyosarcoma (one patient), left inguinal region leiomyosarcoma (one patient), retroperitoneal liposarcoma (one patient) and cholangiocellular carcinoma (one patient). Median duration of SD was 4.1 months (range: 1.3-11.1). Two patients in Cohort 2 (lung adenocarcinoma: 1; retroperitoneal leiomyosarcoma: 1) and one patient in Cohort 3 (cholangiocellular carcinoma) received at least 4 months of treatment; the patient in Cohort 2 with lung adenocarcinoma received 11 months of treatment (eight cycles).
Pharmacodynamic effects
After the first dose of ramucirumab in Cohorts 2 and 3, serum levels of VEGF-A, VEGF-D and PlGF increased and remained elevated at 6 weeks relative to baseline levels (Fig. 2) . As noted in the 'Patients and methods' section, samples were not available from Cohort 1 for analysis. Conversely, serum levels for c-KIT decreased following ramucirumab administration. No substantial trends were observed for any of the other assessed biomarkers.
Discussion
This phase 1 study showed that ramucirumab monotherapy in the dose range of 6-10 mg/kg, administered every 2 or 3 weeks, was well tolerated and had an acceptable safety profile in Japanese patients with advanced solid tumors. Following single-dose administration of ramucirumab, C max appeared to increase proportionally with dose in the tested dose range; however, there was no clear trend for a dose-proportional increase in AUC. Consistent with the previously observed mild immunogenic profile for ramucirumab, no patient developed treatment-emergent anti-ramucirumab antibodies during the study. There were signs of disease control activity in this phase 1 study, with approximately half the study population achieving SD. These results are consistent with those observed in phase 1 studies conducted in largely Caucasian study populations and support further investigation of ramucirumab in Japanese patients with advanced solid tumors. Ramucirumab administered at doses of 6 mg/kg Q2W, 8 mg/kg Q2W and 10 mg/kg Q3W had an acceptable safety profile in this population of Japanese patients with advanced solid tumors, with no DLTs, deaths or treatment discontinuations due to AEs. In addition, the majority of AEs were assessed as Grade 1 or 2. The MTD was not reached in this study in which the highest dose tested was 10 mg/kg Q3W. This is consistent with the two phase 1 studies of ramucirumab monotherapy conducted in largely Caucasian study populations with advanced solid tumors. In a phase 1 study that assessed ramucirumab monotherapy over a dose range of 2-16 mg/kg on a weekly schedule (QW), the MTD was 13 mg/kg QW (5). In a phase 1 study that assessed ramucirumab monotherapy at a dose of 6, 8 or 10 mg/kg Q2W and at a dose of 15 or 20 mg/kg Q3W, the MTD was not reached (9) . As observed in other studies of ramucirumab, administered as monotherapy (5, 9, 10, 20, 21) or in combination with chemotherapy (11, 13, 17) , ramucirumab-related AEs included headache, diarrhea, hypertension, fatigue and proteinuria. The most frequently reported ramucirumab-related AEs in this study were evenly distributed across the three cohorts, with the exception of pyrexia and headache, which appeared to occur more frequently at the higher dose levels.
After single-dose administration of ramucirumab in the tested dose range of 6-10 mg/kg in this study, C max appeared to increase proportionally with dose, with no clear trend for a doseproportional increase in AUC. As expected for humanized IgG monoclonal antibodies, ramucirumab had a relative long half-life (129-329 hours). Although cross-study comparisons do not enable definitive conclusions to be drawn, especially for relatively small studies, the PK profile of ramucirumab in this study of Japanese patients supports the recommended dosing and schedules that resulted from the two phase 1 studies of ramucirumab monotherapy conducted in largely Caucasian study populations (5, 9) . In addition, the use of different assays for determination of ramucirumab serum concentrations for the PK analyses further complicates cross-study comparisons. Although the same assay was used in this study and the two previously reported phase 1 studies of ramucirumab monotherapy (5,9), the three phase 1 studies of ramucirumab in combination with chemotherapy (17-19) used a modified assay.
As ramucirumab is a monoclonal antibody, it has the potential to induce the formation of anti-drug antibodies. A low overall incidence of treatment-emergent anti-ramucirumab antibodies has mostly been observed in other studies of ramucirumab monotherapy (5, 9, 10, 20) . In this study, no patients developed treatment-emergent anti-ramucirumab antibodies, providing further evidence for ramucirumab having a mild immunogenic profile.
Although no efficacy conclusions can be drawn from this phase 1 study, a best response of SD was observed in approximately half of the patients, across a variety of tumor types. In addition, three of these patients remained on study for more than 4 months, with one patient remaining on study for 11 months. The efficacy results observed in this study in Japanese patients with advanced solid tumors are in line with those observed in the two phase 1 studies of ramucirumab conducted in largely Caucasian study populations with advanced solid tumors. In the phase 1 study that assessed ramucirumab monotherapy over a dose range of 2-16 mg/kg on a weekly schedule, 4 of 37 patients (11%) had a best response of PR and 23 of 37 patients (62%) had a best response of SD (5). In the phase 1 study that assessed ramucirumab monotherapy at a dose of 6, 8 or 10 mg/kg every 2 weeks and at a dose of 15 or 20 mg/kg every 3 weeks, 15 of 25 patients (60%) had a best response of SD (9) . The randomized phase 3 studies demonstrated improvement in overall survival and other efficacy endpoints in patients with advanced gastric or gastroesophageal junction cancer (11) , with FOLFIRI in patients with metastatic CRC (12) and with docetaxel in patients with stage IV NSCLC (13) . Dose-schedule combination of 8 mg/kg every 2 weeks for gastric and CRC and 10 mg/kg every 3 weeks for NSCLC has been adopted as approved dosing of ramucirumab. The results of this study support the current dosing schedule of this combination therapy.
Increases in serum VEGF-A, VEGF-D and PlGF levels were observed after the first dose of ramucirumab in the patients in this study. This observation for VEGF-A in Japanese patients is in line with findings for VEGF-A in studies of ramucirumab monotherapy conducted in largely Caucasian patient study populations (5, 9, 20) . The increases in serum VEGF-A and VEGF-D levels after administration of ramucirumab are likely a result of ramucirumab displacing these ligands from VEGFR-2, although compensatory upregulation of VEGF-A and VEGF-D might also contribute to the increase. The increase in serum levels of PlGF observed in Japanese patients after administration of ramucirumab is consistent with results previously observed in patients with hepatocellular carcinoma (20) . This increase in PlGF may result from compensatory upregulation in the VEGFR-1 pathway following VEGFR-2 inhibition by ramucirumab and/or increased binding of VEGFR-1 by VEGF because of the blockade of VEGF binding to VEGFR-2 by ramucirumab. Overexpression of c-KIT is known to occur in many tumor types (22) and has been noted as a potential poor prognostic factor (23) . It has been postulated that there may be signaling interactions between the VEGFR and c-KIT receptors (23) . Given the complexity and the uncertainty in the role of c-KIT in angiogenesis, the mechanism for the observed decrease in c-KIT levels following ramucirumab administration is not known. Additionally, the clinical significance of the observed changes for each of these markers is unknown. Research is ongoing in other ramucirumab trials to further understand biomarker relationships.
Limitations of this study included its small sample size, which is inherent to this study design, and serum concentration data following repeated dosing being available for only a small number of patients.
In conclusion, ramucirumab was well tolerated and feasible at the doses and schedules used in this phase 1 study conducted in Japanese patients with advanced solid tumors. The PK profile of ramucirumab in this Japanese study population supports the recommended dosing and schedules of ramucirumab monotherapy derived from phase 1 studies conducted in largely Caucasian study populations. No CR or PR was observed, but 3 of 15 patients received at least 4 months of treatment. Taken together, these results support the current dosing schedule of combination therapies for gastric cancer and CRC (8 mg/kg Q2W) and for NSCLC (10 mg/kg Q3W). 
